[ad_1]
Jakarta, CNBC Indonesia – In order to lead a normal life, Indonesia is increasingly aggressive in purchasing the corona virus vaccine.
Recently, the government managed to secure a commitment to purchase 40 million doses of the Covid-19 vaccine. This is an agreement between Bio Farma and Sinovac Biotech China that was witnessed by the Minister of Foreign Affairs, Retno Marsudi, and the Minister of Public Enterprises, Erick Thohir.
So what is the price of the Covid-19 vaccine in Indonesia?
Erick Thohir, executive director of the Committee for the Management of Covid-19 and National Economic Recovery, said that the acquisition of the Sinovac Covid-19 vaccine is a short-term strategy for the government and for the current emergency. However, in the long term, the government will promote the red and white vaccine.
Based on the cooperation signed with Sinovac, the government will pay US $ 8 per dose for the raw material. Next year, the price of this raw material will range between US $ 6 and US $ 7 per dose.
Photo: Infographic / Below is the price list of Covid-19 vaccines / Arie Pratama
|
“These are raw materials because we want to learn how to produce vaccines, not just in terms of receiving ready-to-use vaccines,” Erick Thohir said at a working meeting with the VI Commission of the Indonesian Parliament in the DPR building, Jakarta, on Thursday 8/27/2020).
“Our initial calculation, this vaccine costs between US $ 25 (Rp. 365 thousand) and US $ 30 (Rp. 438 thousand) per person. However, Bio Farma is recalculating the price. Then a person will inject themselves twice within 2 weeks, “he explained. Erick Thohir.
Erick Thohir added that his party also proposed two mass vaccination schemes. Namely, free vaccinations for BPJS Kesehatan participants and standalone vaccinations for some high-income individuals. This is so as not to overload state finances.
For information only, the red and white vaccine is a Covid-19 vaccine developed with a local strain from Indonesia. The development of vaccine seeds is in charge of the Eijkman Molecular Institute.
Yes, according to the clinical trial plan for humans, the red and white vaccine will be carried out in semester II-2021 and the mass production of the vaccine will be carried out in 2022.
[Gambas:Video CNBC]
(dru)